SCHEMBL2474233

SCHEMBL2474233

CC(C)(C)OC(=O)Nc1ccccc1NC(=O)c1ccc(C(CC2CCN(C(=O)OC(C)(C)C)CC2)NC(=O)NC2CCCC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.46
PKM P14618 1/20 0.46
EPHX1 P07099 1/20 0.45
CCR8 P51685 1/20 0.43
TGFBR1 P36897 1/20 0.39
USP30 Q70CQ3 2/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
HDAC1 Q13547 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3835595 0.86 KDM4E (0.45) KDM4EPKMCCR8TGFBR1NPC1
SCHEMBL4391397 0.85 KDM4E (0.47) KDM4EPKMCCR8TGFBR1NPC1
SCHEMBL3832630 0.85 NPC1 (0.51) KDM4EPKMCCR8TGFBR1NPC1
SCHEMBL12051557 0.78 KDM4E (0.46) KDM4EPKMEPHX1CCR8TGFBR1
SCHEMBL20601233 0.77 KDM4E (0.66) KDM4EPKMCCR8TGFBR1NPC1
SCHEMBL20601477 0.76 KDM4E (0.58) KDM4EPKMTGFBR1NPC1ALDH1A1
SCHEMBL20618718 0.76 KDM4E (0.58) KDM4EPKMCCR8TGFBR1MAPK1
SCHEMBL3830420 0.76 KDM4E (0.59) KDM4EPKMCCR8TGFBR1MAPT
SCHEMBL20601549 0.75 KDM4E (0.59) KDM4EPKMTGFBR1MAPK1KMT2A
SCHEMBL20601482 0.75 KDM4E (0.59) KDM4EPKMKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 KDM4E 1820/4885PKM 2000/4885EPHX1 2903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.